Zastaprazan for the prEvention of Upper GI Bleeding in Ischemic Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 984 participants.

Also called NCT07730840

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 984 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07730840
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07730840. Randomized; quadruple masking; primary purpose treatment. Start 2026-10-15 (anticipated); primary completion 2029-09-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Zastaprazan for the prEvention of Upper GI Bleeding in Ischemic Stroke
Intervention (Drug)
Zastaprazan
Intervention (Drug)
Placebo
Lead sponsor
Asan Medical Center (class: other)
Collaborator
Jeil Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07730840
Content hash
8b48e0433e417948607a7d58da7621fe1ca5ac3c430b82cde1e15be85a1bfd2e